All Topic Areas
1 - 10 of 120 more >>
Articles
1 - 3 of 3
- FDA Approves First Oral Fluid Based Rapid HIV Test Kit
FDA today approved the use of oral fluid samples with a rapid HIV diagnostic test kit that provides screening results with over 99 percent accuracy in as little as 20 minutes. Until now, all rapid HIV tests required the use of blood in order to get such rapid results. The original version of this rapid test -- the OraQuick Rapid HIV-1/2 Antibody Test, manufactured by OraSure Technologies, Inc., Bethlehem , Pa. -- was approved November 7, 2002 for detection of antibody to HIV-1 in blood. On...
U.S. Food and Drug Administration
- AcuTect, Kit Consumer Information
AcuTect is a radioactive imaging test used to diagnose acute venous thrombosis (sudden blood clots) in the legs. AcuTect appears to detect acute and not chronic venous thrombosis. If you are experiencing the signs and symptoms of acute venous thrombosis, your doctor will determine whether or not to withhold any anticoagulant drugs (drugs used to thin the blood) that you may be taking. This decision should not be based on a negative AcuTect study alone. If you have a history of drug reactions,...
U.S. Food and Drug Administration
- NeoTect Kit Consumer Information
NeoTect is a radioactive imaging test used to evaluate certain lung lesions in patients who test positive for lung lesions using other imaging tests (e.g., CT or MRI) and have been diagnosed with cancer or have a strong likelihood of cancer. NeoTect identifies certain cells that may be associated with lung cancer and sometimes with other conditions. If there is a history of drug reactions or allergies, emergency equipment and health care professionals trained to recognize and treat severe...
U.S. Food and Drug Administration
News
1 - 5 of 339 more >>
- New home impotency test kit available for embarrassed men
The Earth Times - Sun, 18 Feb 2007 04:37 EST
- Androgen Receptor Decoy Molecules Block The Growth Of Prostate Cancer
MedicalNewsToday - Mon, 26 Feb 2007 08:00 EST
- Study Advances Evidence for Receptor’s Role in Alcohol Pleasure and Problems - March - 06, 2007
National Institutes of Health - Tue, 06 Mar 2007 08:40 EST
- High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel In Androgen-Independent Prostate Cancer
MedicalNewsToday - Mon, 05 Mar 2007 08:00 EST
- FDA Approves Astellas' Vaprisol(R) For The Treatment Of Hypervolemic Hyponatremia
MedicalNewsToday - Sat, 03 Mar 2007 08:00 EST
Clinical Trials
1 - 5 of 189 more >>
- Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00232505 - Active, not recruiting
Breast Cancer
- Home Usage of Conception Kit Instructions
ClinicalTrials.gov Identifier: NCT00326651 - Active, not recruiting
Healthy
- Trial of Letrozole Plus OSI-774 (Tarceva) in Post-Menopausal Women With Estrogen Receptor (ER) and/or Progesterone Receptor (PR)-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00179296 - Recruiting
Breast Cancer; Neoplasm Metastasis
- Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00573755 - Recruiting
Breast Cancer
- Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
ClinicalTrials.gov Identifier: NCT00050011 - Active, not recruiting
Breast Neoplasms; Osteoporosis

Not Signed In -

